Is It Too Late To Consider Albemarle (ALB) After A 205% One Year Surge?

• If you are wondering whether Albemarle is still attractively priced after its recent run, or if the easier gains may already be behind it, this article breaks down what the current share price might be implying.
• The stock has climbed 25.3% year to date and 204.8% over the past year, even though it is down 11.4% over the last week and 2.7% over the past month from a last close of US$180.38.
• Recent headlines around Albemarle have focused on its role in key materials markets and changing sentiment around future demand, which helps explain why the share price has been so active. At the same time, debates about long-term growth expectations and risk have kept valuation firmly in the spotlight for investors following the stock.
• On Simply Wall St's valuation checks, Albemarle scores a 2 out of 6. The rest of this article will unpack how different valuation methods assess the stock today and introduce a more detailed way to think about value by the end.

Albemarle scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Albemarle Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and then discounting them back to today’s dollars. It is essentially asking what future cash generation is worth right now.

For Albemarle, the model used is a 2 Stage Free Cash Flow to Equity approach built on cash flow projections. The latest twelve month free cash flow is a loss of about US$106.0 million. Looking ahead, analyst and extrapolated projections used in the model show free cash flow rising into the hundreds of millions of US dollars, with an estimated US$1.68 billion by 2030 and further projections through 2035 provided by Simply Wall St.

Bringing all those projected cash flows back to today’s value results in an estimated intrinsic value of about US$353.57 per share. Compared with the recent share price of US$180.38, this implies Albemarle trades at roughly a 49.0% discount. On this DCF view, the stock appears materially undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Albemarle is undervalued by 49.0%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Albemarle.

Approach 2: Albemarle Price vs Sales

For companies where earnings can be volatile, the P/S ratio is often a useful way to compare valuation because it focuses on revenue rather than profit, which can swing with one off items or investment cycles.

In general, higher growth expectations and lower perceived risk tend to justify a higher “normal” trading multiple. Slower growth or higher risk usually point to a lower multiple being reasonable.

Albemarle currently trades on a P/S of 3.87x. This sits above both the Chemicals industry average of 1.18x and the peer group average of 2.83x. On those simple comparisons, the stock screens as more expensive than many industry peers.

Simply Wall St’s Fair Ratio metric goes a step further by estimating what a suitable P/S might be after factoring in elements like earnings growth, profit margins, industry, market cap and specific risks. For Albemarle, the Fair Ratio is 2.04x, which is lower than the current 3.87x P/S. On this framework, the stock screens as overvalued relative to what those fundamentals might support.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Albemarle Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Simply Wall St’s Narratives let you pick a story for Albemarle, connect that story to specific forecasts for revenue, earnings and margins, and translate it into a Fair Value that you can compare with the current share price. This can help you decide whether the stock looks attractive or stretched. The platform then keeps that Narrative updated as new news or earnings arrive. A more optimistic Albemarle Narrative might align with a Fair Value of about US$264 based on faster growth and higher margins, and a more cautious Narrative might sit closer to US$58 based on slower growth and lower profitability. All of this is available within an easy to use Community page that millions of investors access to see how different viewpoints stack up against the live market price.

For Albemarle however we'll make it really easy for you with previews of two leading Albemarle Narratives:

🐂 Albemarle Bull Case

Fair Value: US$264.00

Implied discount vs this Fair Value: about 31.7% relative to the recent US$180.38 share price

Revenue growth assumption: 15.80% per year

• Focuses on cost and productivity gains, with Albemarle already reaching the high end of a US$400m savings target earlier than planned. The bullish view links this to stronger future margins.
• Suggests that global electrification and tighter lithium supply could support higher volumes and pricing power over time, potentially lifting revenue and earnings beyond consensus assumptions.
• Recognises meaningful risks around lithium prices, geopolitics, technology shifts and regulation, but argues that if optimistic analyst assumptions on revenue, margins and a 14.1x P/E in 2029 hold, a Fair Value of US$264 is reasonable.

🐻 Albemarle Bear Case

Fair Value: US$172.62

Implied premium vs this Fair Value: about 4.5% relative to the recent US$180.38 share price

Revenue growth assumption: 7.91% per year

• Anchors on a consensus style view that lithium pricing and industry oversupply could limit Albemarle's pricing power, leaving only moderate upside to the Fair Value estimate.
• Highlights that cost cuts, lower capital spending and long term contracts support cash flow and stability, but may also cap future volume growth if underinvestment persists.
• Points to risks from prolonged low lithium prices, potential overcapacity, policy and regulatory changes and alternative battery technologies, with a Fair Value of about US$172.62 reflecting these uncertainties.

If you want to see how the wider community is weighing up these bullish and more cautious Albemarle stories side by side, including the third Narrative that also factors in risks and valuation, See what the community is saying about Albemarle.

Do you think there's more to the story for Albemarle? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com